BCPS key terms

The study of how the body absorbs, distributes, metabolizes, and eliminates a drug over time, describing the relationship between a dose given and the concentration achieved at its site of action.

A theoretical volume that relates the total amount of drug in the body to its measured plasma concentration; a large value suggests wide tissue distribution rather than confinement to the bloodstream.

The time needed for plasma drug concentration to fall by half; it predicts time to steady state, guides dosing interval selection, and estimates how long effects persist after a drug is stopped.

An initial, larger dose calculated from volume of distribution and a target concentration so that therapeutic levels are reached quickly, after which maintenance dosing sustains those concentrations.

Measuring serum drug concentrations at defined times to individualize dosing for drugs with narrow therapeutic ranges or unpredictable kinetics, guiding adjustments that preserve efficacy while limiting toxicity.

A property of drugs for which small differences in dose or concentration cause clinically important changes in benefit or harm, requiring careful titration and often concentration monitoring.

A harmful and unintended response to a drug given at normally used doses; it is assessed for causality and severity and reported to surveillance programs when serious.

Reduction of metabolic enzyme activity by one drug, which slows clearance of co-administered substrates and raises their concentrations, sometimes precipitating clinically significant toxicity.

The study of how inherited genetic variation affects drug metabolism, transport, or target response, used to predict individual differences in efficacy and in the risk of adverse effects.

Coordinated program activities that promote appropriate antimicrobial selection, dosing, duration, and route, aiming to improve outcomes while reducing resistance, toxicity, and unnecessary cost.

A pharmacokinetic exposure index that compares 24-hour vancomycin area under the curve with the pathogen's minimum inhibitory concentration, used to target efficacy while limiting nephrotoxicity.

A formula that estimates creatinine clearance from age, weight, sex, and serum creatinine, widely used to adjust doses of renally eliminated medications in adults.

A hierarchy that ranks study designs by their susceptibility to bias, typically placing systematic reviews of randomized trials at the top and expert opinion or mechanistic reasoning at the bottom.

A protocol-driven synthesis that identifies, appraises, and combines all relevant studies addressing a focused question, often pooling effect estimates through meta-analysis.

Analyzing participants according to the group to which they were originally randomized regardless of adherence or crossover, preserving randomization's protection against bias but diluting estimated effects.

The reciprocal of the absolute risk reduction, expressing how many patients must receive an intervention for one additional patient to gain benefit over a specified time period.

A range around a study's point estimate that, with a stated probability, contains the true population value, conveying both the size and the precision of an observed effect.

The probability of obtaining results at least as extreme as those observed if the null hypothesis were true; it indicates statistical compatibility with chance but not effect size or clinical importance.

Variation in effect estimates among pooled studies that exceeds what chance alone would produce, quantified by statistics such as I-squared and used to judge whether combining results is meaningful.

The tendency for studies with positive or statistically significant findings to be published more readily than null studies, distorting pooled estimates and often explored with funnel plots.

Distortion of an observed exposure-outcome relationship by a third variable linked to both; it is controlled through randomization, restriction, matching, stratification, or multivariable adjustment.

A trial designed to show that a new treatment is not unacceptably worse than an active comparator by more than a prespecified margin, often when the new option offers safety or convenience advantages.

A structured framework for rating certainty of evidence and strength of recommendations, weighing risk of bias, inconsistency, indirectness, imprecision, and publication bias.

An economic evaluation that compares costs and health outcomes across alternatives, often reported as an incremental cost-effectiveness ratio expressing cost per quality-adjusted life-year gained.

A drug that carries an elevated risk of substantial patient harm when used in error, such as anticoagulants, insulin, or opioids, and therefore requires standardized safeguards and independent checks.

A structured comparison of a patient's complete medication list across care transitions to identify discrepancies, prevent errors, and confirm which therapies should be continued or stopped.

A structured retrospective method for uncovering the underlying system failures and contributing factors behind a serious adverse event, producing corrective actions rather than individual blame.

A prospective team-based technique that maps a process, identifies where steps could fail, and prioritizes fixes according to the likelihood, severity, and detectability of resulting harm.

A rapid improvement method in which a change is planned, tested on a small scale, studied for its results, and then adopted, adapted, or abandoned, repeated iteratively to refine processes.

An organizational approach that balances accountability with learning: honest errors are supported and disclosed, reckless behavior is addressed, and flawed systems are fixed rather than concealed.

A continually managed list of medications approved for use within an organization, maintained by a pharmacy and therapeutics committee using evidence on efficacy, safety, and cost.

A performance improvement activity that assesses whether medications are prescribed, dispensed, administered, and monitored appropriately, then implements changes to correct identified practice gaps.

A set of adult learning principles holding that learners are self-directed, bring prior experience, need perceived relevance, and prefer problem-centered application over passive content delivery.

Units of professional practice that supervisors entrust to trainees at progressively higher levels of independence as competence is demonstrated, linking competency frameworks to real clinical work.

Supervising and teaching learners in practice settings through direct observation, role modeling, questioning, feedback, and graded independence to build clinical competence and confidence.

Specific, timely, behavior-focused information about performance relative to expectations, delivered supportively so that it reinforces strengths and guides concrete improvement.

Objectives framed as specific, measurable, achievable, relevant, and time-bound, giving learners and staff clarity about expectations and a basis for judging progress.

Structured approaches for guiding people and systems through organizational transitions, addressing communication, stakeholder engagement, and reinforcement so that new practices are sustained.

Ongoing self-directed learning that maintains and advances competence through needs assessment, planned activities, reflection, and application to practice, extending beyond initial licensure and training.